Table of Contents (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38302 NRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Delaware 82-2844431 (Sta ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Robert Besthof ??? Interim Chief Executive Officer, Head of Operations & Chief Commercial Officer Tom Johnson ??? Investor Relations Ira Strassberg ??? Chief Financial Officer and Treasurer Conference Call Participants Operator Greetings and welcome to NRX Pharmaceuticals First Quarter 2022, Earnings Conference Call. At this time, all participants are in listen-only mode. [Operator Instructi ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2021 Earnings Conference Call March 31, 2022 8:30 AM ET Company Participants Eric Goldstein - MD, LifeSci Advisors, IR Robert Besthof - Interim CEO, Head of Operations & Chief Commercial Officer Ira Strassberg - CFO and Treasurer Conference Call Participants Operator Greetings and welcome to the NRx Pharmaceuticals Full Year 2021 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38302 NRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 82-2844431 (State or ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2021 Earnings Conference Call November 16, 2021 8:30 AM ET Company Participants Eric Goldstein - Managing Director, LifeSci Advisors Jonathan Javitt - Chairman and Chief Executive Officer Randy Guggenheimer - Chief Business Officer Operator Good morning, everyone and welcome to the NRx Pharmaceuticals??? Third Quarter Results and Conference Call. Currently, participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference call is being ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39412 NRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other juri ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q2 2021 Results Conference Call August 17, 2021 8:30 AM ET Company Participants Eric Goldstein - Managing Director, LifeSci Advisors Jonathan Javitt - Chairman and Chief Executive Officer Randy Guggenheimer - Chief Business Officer Robert Besthof - Chief Commercial Officer Operator Greetings, and welcome to the NRx Pharma Second Quarter 2021 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal pr ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39412 NRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdict ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-38302 BIG ROCK PARTNERS ACQUISITION CORP. (Exact name of registrant as specified in its charter) ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38302 BIG ROCK PARTNERS ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 82-2844431 (State or othe ...